Journal of Medical Genetics and Clinical Biology
Homepage : https://journal.antispublisher.id/index.php/JMGCB
Email : admin@antispublisher.com

e-ISSN : 3032-1085
JMGCB, Vol. 2, No. 5, May 2025
Page 185-192

Out Comes After CAR T Cell Therapy in The Long Run

Samaa Faez
University of Thi-Qar, Iraq

Check for updates OPEN ACCESS

DOI : https://doi.org/10.61796/jmgcb.v2i5.1297

Sections Info

Article history:
Submitted: March 31, 2025
Final Revised: April 15, 2025
Accepted: April 29, 2025
Published: May 16, 2025

Keywords:
Chimeric antigen receptor T cell
Immunotherapy
Opposing reactions mechanism
Adapting strategies
Downsides
Adversal impacts

ABSTRACT

Objective: *During the past several years, there has been a lot of discussion regarding the utilization of chimeric antigen receptor T-cells as an immunotherapy treatment for malignancies.* ***Method:*** *The scope of this study encompasses not only the negative consequences that CAR-T cells have, but also the mechanisms that are responsible for those effects, as well as potential treatments.* ***Results:*** *Through the utilization of this therapy strategy, both hematological malignancies and solid tumors have been successfully treated. However, it has been associated with a number of adverse reactions, such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), off-target effects, anaphylaxis, infections associated with CAR-T cell infusion (CTI), tumor lysis syndrome (TLS), B-cell dysplasia, hemophagocytic lympho histiocytosis (HLH)/macrophage activation syndrome (MAS), and coagulation disorders.* ***Novelty:*** *The therapeutic application of CAR-T cell therapy can be informed by this evaluation, which will furnish critical reference data.*

INTRODUCTION

Many studies have examined potential cancer treatments. The 2018 Nobel Prize in physiology or medicine was bestowed upon American immunologist "James P. Alison and Japanese immunologist Tasuku Honjo "for their contributions to tumor immunity. The study's findings pave the way for future research into tumor immunotherapy and its potential use in the treatment of many types of cancer. A kind of tumor immunotherapy, CAR-T cell therapy has recently been the subject of substantial study and use in cancer treatment. Specifically, CARs have the ability to target molecules found on the surface of cells.

Contrary to TCR-modified T cells, CAR doesn't require processing of antigens or presentation of HLA. Therefore, it is applicable to a diverse set of patient populations defined by their HLA types [1], [2]. There are major risks associated with CAR-T cell treatment, including the potential for fatal side effects, despite the technique's apparent promise in treating hematological tumors.

The possible adverse effects of CAR-T cell treatment are addressed in this article, along with their development and methods to mitigate their severity. To better manage CAR-T cell therapy-related adverse effects, clinicians can utilize the findings of this study as a basis.

RESEARCH METHOD

This study employed a qualitative literature review approach to investigate the long-term side effects and clinical outcomes of CD19-targeted CAR T cell therapy in

cancer treatment. Data were collected from a wide range of published clinical trials, case reports, and cohort studies spanning the past decade, focusing on late-onset complications such as neurotoxicity, infections, cytopenia, organ-specific toxicities, fertility issues, and immune function recovery. Articles included were selected based on relevance, citation frequency, and the presence of follow-up data exceeding 24 months post-infusion. The findings were synthesized to identify consistent patterns and highlight potential management strategies for adverse events associated with CAR T cell therapy.

RESULTS AND DISCUSSION

Long-Term Outcomes

"CD19-targeted CAR T cells were used to treat B cell lymphoma and chronic lymphocytic leukemia"

It is the premature trial participants who got CD19-targeted CAR T cell treatments for R/R B cell lymphoma or chronic lymphocytic leukemia (CLL) who provide the majority of the data on long-term results following CAR T cell infusion (Table 1). These individuals were treated with CAR T cells. A total of 10 studies have been conducted, each of which has provided follow-up data for a duration of at least twenty-four months (ranging from twenty-four to one hundred and three months) [3], [4], [5], [6]. The findings indicate that the CR rates range from 28 to 68%, and the ORRs ranging from 44 to 91% are among the most common. Every single investigation discovered that there was a subset of patients who remained to display continuous reactions at least two years following the infusion, even though there was no consolidative medicine being delivered. All malignancies that were treated, including aggressive B cell lymphomas, follicular lymphomas, mantle cell lymphomas, and chronic lymphocytic leukemia, as well as all CD19-targeted CAR T cell treatments that are currently licensed, were found to achieve these long-term durable remissions [3], [4], [5], [6]. "We wanted to analyze the outcomes for patients who had received this kind of treatment, so we carried out one of the longest follow-up studies ever conducted on CD19-targeted CAR T cells," the researchers said.

Late-Onset Orpersistent Neuro Poison

CRS and ICANS are often early difficulties that manifest themselves within the first one to two weeks after CAR-T cell infusion. This coincides with the process of CAR-T cells reaching their highest level of activation and proliferation. [7]: There is a possibility that as many as ten percent of patients will experience delayed onset ICANS. This condition can manifest itself as disorientation and seizures anywhere from three to four weeks after the infusion. This highlights the importance of maintaining neurologic surveillance throughout the first month. It has been documented [8] in case reports that severe and potentially fatal ICANS have occurred as late as six to nine months after treatments had been administered. [9], [10] It is recommended that individuals who have received CAR-T cells refrain from driving or operating heavy machinery for a period of eight weeks. This is because there is a possibility of late-onset and/or protracted neurotoxicity. [11] Patients who are suspected of having late-onset neurotoxicity require evaluation through the use of magnetic resonance imaging (MRI) of the brain and

cerebrospinal fluid (CSF) examination. This is done in order to rule out other potential causes, such as recurrent malignancy, bleeding, stroke, or infection. The standard treatment for inflammatory cytokine-associated neurotoxicity syndrome (ICANS) includes supportive care, corticosteroids, and maybe other immunosuppressive drugs. The management of late-onset neurotoxicity is consistent with this treatment technique. After receiving ICANS treatment, individuals who are elderly or more frail may be more likely to experience prolonged deconditioning and myopathy caused by corticosteroids caused by the medication. This underscores the importance of providing geriatric assessment, physiotherapy, nutritional aid, and rehabilitation services to this population that is at risk [12], [13], [14]. In most cases, ICANS is characterized by a spontaneous cure, with the average duration of symptoms being 8.3 ± 10.5 days. On the other hand, there is a possibility that mild but long-lasting declines [15] in neurocognitive performance and executive function will occur over the course of the subsequent one to three months, which will finally result in recovery within a year. [16] In addition, chronic neurological and/or psychological symptoms include: People who have received CAR-T cells have reported experiencing symptoms such as neuropathy, cognitive impairment, cerebrovascular accidents, and mental problems for a length of time spanning from one to five years [17], [18], [19]. These symptoms have been reported by an estimated ten percent to forty-eight percent of those who have received CAR-T cells.

Late Infections

Despite the fact that CRS and ICANS are the most significant toxicities associated with CAR-T cell therapy, these problems have become more controllable as a result of the deployment of standardized treatment methods. These procedures include the quick injection of tocilizumab and corticosteroids. The numbers [20], [21] The majority of fatalities that do not occur as a result of relapse after having CAR-T cell therapy are predominantly caused by late infections rather than CRS or ICANS. This is the case even if relapse is a secondary cause of death. [22], [23], [24] The frequency of non-relapse mortality (NRM) was found to be 4.9% one year following CAR-T cell infusion, according to the findings of a study that included 977 patients with leukaemia-related chronic lymphocytic leukemia (LBCL). Infections were the cause of death for fifty-two percent of the deaths that did not involve recurrence. A total of forty-two Previous cancer treatments such as HCT, bridging therapies, lymphodepleting chemotherapy, corticosteroid administration for CRS and ICANS, prolonged neutropenia, and delayed immune reconstitution are some of the factors that can increase the likelihood of infection following CAR-T cell therapy [25]. Other factors that can increase the likelihood of infection include immune dysregulation as a result of the underlying cancer. One of the risks linked with CD19-directed CAR-T cell therapy is the development of seventy-three B-cell aplasia, which is both on-target and off-tumor. This toxicity has the potential to last in ongoing responders for up to "1 and 2 years" in fifty percent and twenty-five percent of patients with leukemia-like cell lymphoma "(LBCL)" and seventy-one percent and fifty-nine percent of patients with basal cell lymphoma (B-ALL), respectively.[26] [27] A patient's vulnerability to recurrent and/or severe infections, such as respiratory viruses,

sino-pulmonary infections, and encapsulated bacteria, may be raised if they have hypogammaglobulinemia [25]. This is because hypogammaglobulinemia is a condition that inhibits the production of gamma-globulin.

Continued Cytopenes

Cytopenia, which can take the form of anaemia, thrombocytopenia, or neutropenia, is one of the acute side effects of CAR T cell therapy that occurs the most frequently [28], [29]. Multiple clinical trials have also discovered the presence of chronic cytopenias that continue to exist for a period of at least three months after the infusion of CAR T cells. At the very least three months after receiving CAR T cell infusion, around fifteen percent of patients diagnosed with B cell lymphoma will develop cytopenias of grade three to four [30], [31]. According to the findings of a long-term follow-up study [32], three out of nineteen patients with B cell malignancies in CR exhibited clinically significant cytopenias for fifteen to twenty-two months after receiving CD19-targeted CAR T cell treatment. This represents sixteen percent of the total number of patients. Similarly, it is worth noting that even after 100 days have passed since the infusion of idecabtagene vicleucel, patients diagnosed with multiple myeloma may still exhibit grade ≥3 neutropenia in "20%" of instances, and thrombocytopenia in "47%" of cases [34]. Ciltacabtagene autoleucel autoleucel is another typical problem that might occur [33]. Despite the fact that persistent cytopenias following CAR infusion are frequently reported in patients who are in continued remission and do not exhibit any indications of "myelodysplastic syndrome (MDS)", the mechanisms that are responsible for these occurrences are still not fully understood [33,34,30,31 35]. The possibility of cytopenias is associated with a greater grade of chronic renal failure (CRF), numerous previous lines of treatment, having received allogeneic HSCT within the year before CAR T cell infusion, having baseline cytopenia, and having bone marrow cancer [35], [36].

Additional Toxicities to Organs

In the acute period that follows CAR T-cell therapy, organ-specific toxicities have been observed. These toxicities include cardiac, pulmonary, and renal toxicities that are related with cytokine release syndrome. [37], [38] Following the clearance of the acute inflammatory condition, these effects often become more pronounced, as evidenced by the experiences that have been documented up to this point, particularly in adult patients. [39] It is possible that local inflammation at extramedullary disease sites, such as pulmonary and peri-ocular areas, may correlate with different toxicities in patients with B-ALL. The numbers [40], [41], [42] Different monitoring and treatment options are required in order to address the issue of tumor inflammation-associated neurotoxicity, which is becoming more prevalent as CAR T cell therapies that target brain tumors continue to improve [43]. In order to evaluate novel CAR T-cell targets across a wide range of cancers, it is necessary to have a heightened understanding of the possible on-target and off-tumor consequences. In order to determine the delayed toxicities of CAR T-cell therapy on systems that are particularly relevant to children and young adults, it is required to conduct a complete evaluation. Psychosocial variables, endocrine function, maturation, and metabolic processes are all included in this category. In addition, it is of

the utmost importance to evaluate the long-term risk profile of "CAR T-cell" therapy in comparison to that of other therapeutic approaches [44].

Fertility Subsequent to CAR T Cell Therapy

Cancer survival dramas usually focus on "children and adolescents" and conception issues. Prior to treatment, realistic and age-appropriate fertility preservation guidelines [45], [46] help cancer survivors improve their quality of life. In acute leu ke mia, fer tility pres er vaction may not be possible before action, and lingering discomfort in sanc tuary regions such the ovary [47] is difficult. Gonadal toxicity from myeloablative HCT with TBI or busul fan causes irreversible infertility in most individuals. Nine hundred sixty-one Concerns about preexisting infertility and the need to reach CAR T cells quickly limit fertility conversations in refractory patients who have received multiple lines of therapy, possibly including myeloablative HCT. Still, some people who have had children after using "CAR T cells (either fathered a kid or fell pregnant with a live delivery)" have been briefly recorded [48] using extra CAR T cells to spare HCT and/or more chemotherapy. "Certainly, the proportion of patients in which fertility could be pre served may rise when CAR T cells are used earlier, thus fully addressing fertility problems in the peri CAR T cell milieu moving forward becomes very vital".

Restoration of Immune Function

One of the potential adverse effects of CD19 CAR T cell therapy is the development of B cell aplasia, which can serve as a surrogate marker for the ongoing presence of CAR T cells. Aplasia of the B-cells can last anywhere from a few weeks to several years, depending on the severity of the condition. [49] Although Bcell aplasia and hypogammaglobulinemia are the causes of a humoral immune deficit, prolonged CAR Tcell persistence is beneficial for the prevention of relapse. This strategy has not been tested on children, despite the fact that immune globulin supplementation is sometimes discontinued in adults when persistent hypogammaglobulinemia does not result in any more infections. [50] Due to the fact that immune reserve is based on plasma cell mass, which increases with age, it is not possible to instantly adapt the information gained from working with adults to managing young patients. [51] Additionally, immune globulin support is being considered for those who are having CAR Tcell therapy. Antimicrobial prophylaxis is also being seriously considered. There is a lack of clarity regarding the ideal length of prophylaxis against herpes simplex virus and Pneumocystis jiroveci pneumonia" (PJP)". However, it is typically recommended that these medications be taken at least once every hour until the "CD4+ lymphocyte levels" surpass 200/μL. Various other fungal and bacterial preventive practices are described in [54], [52], [53], for instance, and these activities may take into consideration the length of neutropenia.

CONCLUSION

Fundamental Finding : CD19-targeted CAR T cell therapy demonstrates durable long-term remissions in patients with relapsed/refractory B cell lymphoma and chronic lymphocytic leukemia, with complete response rates ranging from 28% to 68% and overall response rates between 44% and 91%. Sustained remission beyond two years was

observed across multiple studies, indicating the potential of CAR T cells to achieve lasting disease control without further consolidation therapy. **Implication :** These findings highlight the transformative potential of CD19-directed CAR T cell therapies in hematologic malignancies, suggesting their early integration into treatment protocols could improve survival and reduce the need for more aggressive interventions. However, long-term patient management requires careful attention to late-onset toxicities such as neurotoxicity, infection, cytopenias, and organ-specific effects, as well as considerations for fertility and immune reconstitution. **Limitation :** Despite promising results, most data derive from small cohorts and early-phase trials with limited ethnic and biological diversity. There is also a lack of uniform criteria to assess late toxicities, and persistent cytopenias, infections, and neurocognitive issues remain poorly understood. Furthermore, the balance between durable CAR T cell persistence and immune system recovery is still not fully established. **Future Research :** Longitudinal and multicenter studies are needed to clarify the mechanisms underlying delayed toxicities and to optimize supportive care strategies. Future work should also explore CAR T cell use in earlier lines of therapy, pediatric-specific effects, fertility outcomes, and the development of novel CAR constructs with reduced toxicity profiles. Understanding the interplay between immune reconstitution and infection risk will be essential for refining long-term patient care.

REFERENCES

[1] M. Kalos and C. H. June, "Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology," Immunity, vol. 39, no. 1, pp. 49–60, Jul. 2013, doi: 10.1016/j.immuni.2013.07.002.

[2] M. Sadelain, R. Brentjens, and I. Rivière, "The basic principles of chimeric antigen receptor design," *Cancer Discovery*, vol. 3, no. 4, pp. 388–398, Apr. 2013, doi: 10.1158/2159-8290.cd-12-0548.

[3] K. M. Cappell *et al.*, "Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy," *Journal of Clinical Oncology*, vol. 38, pp. 3805–3815, 2020.

[4] F. L. Locke *et al.*, "Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma," *New England Journal of Medicine*, vol. 386, pp. 640–654, 2022.

[5] E. A. Chong, M. Ruella, and S. J. Schuster, "Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy," *New England Journal of Medicine*, vol. 384, pp. 673–674, 2021.

[6] T. Siddiqi *et al.*, "Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL," *Blood*, vol. 139, pp. 1794–1806, 2022.

[7] E. C. Morris, S. S. Neelapu, T. Giavridis, and M. Sadelain, "Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy," *Nature Reviews Immunology*, vol. 22, no. 2, pp. 85–96, 2022.

[8] S. S. Neelapu *et al.*, "Chimeric antigen receptor T-cell therapy–assessment and management of toxicities," *Nature Reviews Clinical Oncology*, vol. 15, no. 1, pp. 47–62, 2018.

[9] T. Badar, B. D. Johnson, and M. Hamadani, "Delayed neurotoxicity after axi-cabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma," *Bone Marrow Transplantation*, vol. 56, no. 3, pp. 683–685, 2021.

[10] S. Jung, J. Greiner, S. von Harsdorf *et al.*, "Fatal late-onset CAR T-cell mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma," *Blood Advances*, vol. 5, no. 19, pp. 3789–3793, 2021.

[11] U.S. Food and Drug Administration (FDA), "Highlights of prescribing information: Yescarta," 2022. [Online]. Available: https://www.fda.gov/media/108377/download..

[12] O. Obaisi, R. C. Fontillas, K. Patel, and A. Ngo-Huang, "Rehabilitation needs for patients undergoing CAR T-cell therapy," *Current Oncology Reports*, vol. 24, no. 6, pp. 741–749, 2022.

[13] R. J. Lin *et al.*, "Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for

older lymphoma patients," *Blood Advances*, vol. 7, pp. 3501–3505, 2023.
[14] I. Roy *et al.*, "Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma," *British Journal of Haematology*, vol. 197, no. 1, pp. 71–75, 2022.
[15] S. J. Grant *et al.*, "Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review," *Transplantation and Cellular Therapy*, vol. 28, no. 6, pp. 294–302, 2022.
[16] A. I. Hoogland, A. Barata, J. Logue *et al.*, "Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy," *Transplantation and Cellular Therapy*, vol. 28, no. 6, pp. 305.e1–305.e9, 2022.
[17] A. Cordeiro *et al.*, "Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells," *Biology of Blood and Marrow Transplantation*, vol. 26, no. 1, pp. 26–33, 2020.
[18] J. Ruark *et al.*, "Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy," *Biology of Blood and Marrow Transplantation*, vol. 26, no. 1, pp. 34–43, 2020.
[19] A. Barata, A. I. Hoogland, A. Kommalapati *et al.*, "Change in patients' perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma," *Transplantation and Cellular Therapy*, vol. 28, no. 7, pp. 401.e1–401.e7, 2022.
[20] M. S. Topp *et al.*, "Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma," *British Journal of Haematology*, vol. 195, no. 3, pp. 388–398, 2021.
[21] O. O. Oluwole *et al.*, "Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma," *British Journal of Haematology*, vol. 194, no. 4, pp. 690–700, 2021.
[22] K. Rejeski *et al.*, "The CAR-HEMATOTOX risk stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL," *Journal for Immunotherapy of Cancer*, vol. 10, no. 5, p. e004475, 2022.
[23] W. A. Bethge, P. Martus, M. Schmitt, *et al.*, "GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany," *Blood*, vol. 140, no. 4, pp. 349-358, 2022.
[24] J. Lemoine, E. Bachy, G. Cartron, *et al.*, "Causes and risk factors of early and late non-relapse mortality after CD19 CAR T-cell therapy for diffuse large B-cell lymphoma (DLBCL): a Lysa study from the Descar-T registry," *Blood*, vol. 140, pp. 1859-1861, 2022.
[25] J. A. Hill and S. K. Seo, "How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies," *Blood*, vol. 136, no. 8, pp. 925-935, 2020.
[26] T. W. Laetsch, S. L. Maude, S. Rives, *et al.*, "Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial," *J. Clin. Oncol.*, vol. 41, no. 9, pp. 1664-1669, 2023.
[27] F. L. Locke, A. Ghobadi, C. A. Jacobson, *et al.*, "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial," *Lancet Oncol.*, vol. 20, no. 1, pp. 31-42, 2019.
[28] J. N. Brudno and J. N. Kochenderfer, "Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management," *Blood Rev.*, vol. 34, pp. 45-55, 2019.
[29] J. N. Brudno and J. N. Kochenderfer, "Toxicities of chimeric antigen receptor T cells: recognition and management," *Blood*, vol. 127, pp. 3321-3330, 2016.
[30] F. L. Locke, *et al.*, "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial," *Lancet Oncol.*, vol. 20, pp. 31-42, 2019.
[31] J. M. Logue, *et al.*, "Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma," *Haematologica*, vol. 106, pp. 978-986, 2021.
[32] A. Cordeiro, *et al.*, "Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells," *Biol. Blood Marrow Transpl.*, vol. 26, pp. 26-33, 2020.
[33] T. Martin, *et al.*, "Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up," *J. Clin. Oncol.*, vol. 41, pp. 1265-1274, 2023.
[34] N. C. Munshi, *et al.*, "Idecabtagene vicleucel in relapsed and refractory multiple myeloma," *N. Engl. J. Med.*, vol. 384, pp. 705-716, 2021.
[35] J. N. Brudno, *et al.*, "Acute and delayed cytopenias following CAR T-cell therapy: an investigation

of risk factors and mechanisms," *Leuk. Lymphoma*, vol. 63, pp. 1849-1860, 2022.
[36] S. Fried, *et al.*, "Early and late hematologic toxicity following CD19 CAR-T cells," *Bone Marrow Transpl.*, vol. 54, pp. 1643-1650, 2019.
[37] K. S. Hanna, H. Kaur, M. S. Alazzeh, *et al.*, "Cardiotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies: a systematic review," *Cureus*, vol. 14, no. 8, p. e28162, 2022.
[38] H. Liu, Y. Ma, C. Yang, *et al.*, "Severe delayed pulmonary toxicity following PD-L1-specific CAR T-cell therapy for non-small cell lung cancer," *Clin Transl Immunology*, vol. 9, no. 10, p. e1154, 2020.
[39] R. Chakraborty, B. T. Hill, A. Majeed, and N. S. Majhail, "Late effects after chimeric antigen receptor T-cell therapy for lymphoid malignancies," *Transplant Cell Ther.*, vol. 27, no. 3, pp. 222-229, 2021
[40] E. M. Holland, B. Yates, A. Ling, *et al.*, "Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy," *Blood Adv.*, vol. 6, no. 7, pp. 2167-2182, 2022.
[41] S. Khanna, A. G. Mackin, D. T. Dao, *et al.*, "Exudative retinal detachment following chimeric antigen receptor T-cell therapy in relapsed B-cell acute lymphoblastic leukemia," *Ophthalmic Surg Lasers Imaging Retina*, vol. 53, no. 2, pp. 113-115, 2022.
[42] A. A. Mumtaz, A. Fischer, F. Lutfi, *et al.*, "Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review," *Br. J. Ophthalmol.*, vol. 107, no. 7, pp. 901-905, 2023.
[43] J. Mahdi, J. Dietrich, K. Straathof, *et al.*, "Tumor inflammation-associated neurotoxicity," *Nat. Med.*, vol. 29, no. 4, pp. 803-810, 2023.
[44] H. Shalabi, J. Gust, A. Taraseviciute, *et al.*, "Beyond the storm: subacute toxicities and late effects in children receiving CAR T cells," *Nat. Rev. Clin. Oncol.*, vol. 18, no. 6, pp. 363-378, 2021.
[45] R. L. Mulder, A. Font-Gonzalez, D. M. Green, *et al.*, "Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group," *Lancet Oncol.*, vol. 22, no. 2, pp. e57-e67, 2021, doi: 10.1016/S1470-2045(20)30582-9.
[46] R. L. Mulder, A. Font-Gonzalez, M. M. Hudson, *et al.*, "Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group," *Lancet Oncol.*, vol. 22, pp. e45-e56, 2021, doi: 10.1016/S1470-2045(20)30594-5.
[47] T. Zver, S. Frontczak, C. Poirot, *et al.*, "Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients," *J. Ovarian Res.*, vol. 15, no. 1, p. 9, 2022, doi: 10.1186/s13048-021-00936-4.
[48] J. A. Ligon, A. Fry, J. Y. Maher, *et al.*, "Fertility and CAR T cells: current practice and future directions," *Transplant Cell Ther.*, vol. 28, no. 9, pp. 605.e1-605.e8, 2022.
[49] A. Deya-Martinez, A. Alonso-Saladrigues, A. P. Garcia, *et al.*, "Kinetics of humoral deficiency in CAR T-19 treated children and young adults with acute lymphoblastic leukemia," *Bone Marrow Transplant.*, vol. 56, no. 2, pp. 376-386, 2021.
[50] E. Kampouri, C. S. Walti, J. Gauthier, and J. A. Hill, "Managing hypogammaglobulinemia in patients treated with CAR T-cell therapy: Key points for clinicians," *Expert Rev. Hematol.*, vol. 15, no. 4, pp. 305-320, 2022.
[51] J. A. Hill, E. M. Krantz, K. A. Hay, *et al.*, "Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy," *Blood Adv.*, vol. 3, no. 22, pp. 3590-3601, 2019.
[52] K. Wudhikarn and M. A. Perales, "Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy," *Bone Marrow Transplant.*, vol. 57, no. 10, pp. 1477-1488, 2022.
[53] J. A. Hill and S. K. Seo, "How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies," *Blood*, vol. 136, no. 8, pp. 925-935, 2020.
[54] B. D. Santomasso, L. J. Nastoupil, S. Adkins, *et al.*, "Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline," *J. Clin. Oncol.*, vol. 39, no. 35, pp. 3978-3992, 2021.

*__Samaa Faez (Corresponding Author)__
University of Thi-Qar, Iraq
Email: samaa.faez@sci.utq.edu.iq